285 related articles for article (PubMed ID: 37931487)
21. Quality of life and mental health in multiple sclerosis patients during the COVID-19 Pandemic.
Rodríguez-Agudelo Y; Nava-Adán J; Paz-Rodríguez F; Abundes-Corona A; Flores-Rivera J; Corona T
Mult Scler Relat Disord; 2023 Feb; 70():104487. PubMed ID: 36640561
[TBL] [Abstract][Full Text] [Related]
22. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
J Comp Eff Res; 2023 Jan; 12(1):e220127. PubMed ID: 36440609
[No Abstract] [Full Text] [Related]
23. Impact of Covid-19 emergency on rehabilitation services for Multiple Sclerosis: An international RIMS survey.
Brichetto G; Tacchino A; Leocani L; Kos D
Mult Scler Relat Disord; 2022 Nov; 67():104179. PubMed ID: 36130457
[TBL] [Abstract][Full Text] [Related]
24. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
Spierer R; Lavi I; Bloch S; Mazar M; Golan D
J Neurol; 2023 Oct; 270(10):4632-4639. PubMed ID: 37589743
[TBL] [Abstract][Full Text] [Related]
25. Impact of the COVID-19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy.
Colais P; Cascini S; Balducci M; Agabiti N; Davoli M; Fusco D; Calandrini E; Bargagli AM
Eur J Neurol; 2021 Oct; 28(10):3403-3410. PubMed ID: 33896086
[TBL] [Abstract][Full Text] [Related]
26. Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study.
Riley C; Venkatesh S; Dhand A; Doshi N; Kavak K; Levit E; Perrone C; Weinstock-Guttman B; Longbrake E; De Jager P; Xia Z
JMIR Public Health Surveill; 2024 Feb; 10():e45429. PubMed ID: 38319703
[TBL] [Abstract][Full Text] [Related]
27. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
[TBL] [Abstract][Full Text] [Related]
28. Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: A rapid systematic review.
Zarghami A; Hussain MA; Campbell JA; Ezegbe C; van der Mei I; Taylor BV; Claflin SB
Mult Scler Relat Disord; 2022 Mar; 59():103562. PubMed ID: 35149393
[TBL] [Abstract][Full Text] [Related]
29. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
30. The psychological impact of the COVID-19 pandemic on people with multiple sclerosis.
Vacaras V; Nistor C; Schiopu AM; Vacaras C; Marin GE; Muresanu DF
Mult Scler Relat Disord; 2023 Aug; 76():104825. PubMed ID: 37320938
[TBL] [Abstract][Full Text] [Related]
31. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
32. Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels.
Campbell JA; van der Mei I; Taylor BV; Palmer AJ; Henson GJ; Laslett LL; Simpson-Yap S; Claflin SB
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):975-983. PubMed ID: 37884346
[TBL] [Abstract][Full Text] [Related]
33. Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study.
Affinito G; Trama U; Palumbo L; Fumo MG; Giordana R; Di Gennaro M; Triassi M; Lanzillo R; Morra VB; Palladino R; Moccia M
Neurol Sci; 2023 Nov; 44(11):3771-3779. PubMed ID: 37672178
[TBL] [Abstract][Full Text] [Related]
34. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.
Todorović S; Vojinović S; Savić D; Aleksić D; Danilović M
Acta Neurol Belg; 2024 Apr; 124(2):447-455. PubMed ID: 37962785
[TBL] [Abstract][Full Text] [Related]
35. Health care resource utilization and disease modifying treatment use in multiple sclerosis patients by age and insurance type.
Cisternas M; Bartolome L; Gitar B; Hulbert E; Trenz H; Patel V; Johnson K; Russo PA
Curr Med Res Opin; 2021 Apr; 37(4):597-604. PubMed ID: 33535846
[TBL] [Abstract][Full Text] [Related]
36. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
[TBL] [Abstract][Full Text] [Related]
37. The influence of COVID-19 pandemic lockdown on the physical activity of people with multiple sclerosis. The role of online training.
Matysiak M; Siger M; Walczak A; Ciach A; Jonakowski M; Stasiołek M
Mult Scler Relat Disord; 2022 Jul; 63():103843. PubMed ID: 35550480
[TBL] [Abstract][Full Text] [Related]
38. Geographical Variation In Medication and Health Resource Use In Multiple Sclerosis.
Balcom EF; McCombe JA; Kate M; Vu K; Martins KJB; Aponte-Hao S; Luu H; Richer L; Williamson T; Klarenbach SW; Smyth P
Can J Neurol Sci; 2024 Apr; ():1-9. PubMed ID: 38600770
[TBL] [Abstract][Full Text] [Related]
39. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
[TBL] [Abstract][Full Text] [Related]
40. Changes in physiotherapy services and use of technology for people with multiple sclerosis during the COVID-19 pandemic.
Jonsdottir J; Santoyo-Medina C; Kahraman T; Kalron A; Rasova K; Moumdjian L; Coote S; Tacchino A; Grange E; Smedal T; Arntzen EC; Learmonth Y; Pedulla L; Quinn G; Kos D
Mult Scler Relat Disord; 2023 Mar; 71():104520. PubMed ID: 36724646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
